New Zealand · Delayed Price · Currency is NZD Fisher & Paykel Healthcare Corporation Earnings Call Transcripts
Fiscal Year 2026
-
First half revenue rose 14% to NZD 1.089 billion and net profit after tax increased 39% to NZD 213 million, with strong growth in both hospital and home care segments. Full-year guidance was raised, driven by FX and margin improvements, though H2 results may moderate due to seasonality and hardware sales variability.
Fiscal Year 2025
-
Record revenue and profit growth were achieved, with ongoing investment in R&D and infrastructure. The Board emphasized long-term planning, addressed U.S. tariffs, and reaffirmed a 65% dividend payout target. All director elections and resolutions passed, supporting continued global expansion and innovation.
-
Revenue grew 16% to NZD 2.02B and net profit rose 43% to NZD 377.2M, driven by strong hospital and home care growth, margin expansion, and new product launches. FY 2026 guidance anticipates continued revenue and profit growth, with gross margin improvement despite tariff headwinds.
-
First-half revenue rose 18% and net profit after tax increased 43% year-over-year, driven by strong hospital and home care growth, new product launches, and improved margins. Full-year guidance remains unchanged, with expectations for continued growth and margin improvement.
Fiscal Year 2024
-
Revenue and profit grew in FY24, with strong performance in both hospital and home care segments. Board succession and governance were highlighted, alongside infrastructure expansion and new product launches. Key risks addressed included climate, cybersecurity, and product recalls.